I am pleased to share with you our 2022 Annual Report, released at our recent Annual General Meeting on 24 May, 2023. This Annual Report also takes the opportunity to celebrate the 30-year history of CTA.
Please click here to access the report.
As our 2022 report describes, CTA continued its growth trajectory, with increases in both our Membership and service provision. Over the past 18 months we have welcomed five new Members, including our first in Queensland.
CTA is truly national, and for the first time in our history our 37-strong Membership now spans all major Australian states and New Zealand.
Building on the back of growth across the previous five years, almost all CTA service metrics improved again in 2022. Highlights include 232 new trials approved, over 1,100 patients recruited, amendments increased 27%, contract addendums up 35%, and funds transferred to our Members exceeded $41M, an increase of 19% on the previous year.
Building on our transformational information systems project delivered in 2021, we completed the roll out of Clinibase to all service Members in Q1 of 2022. The success of this work positioned CTA perfectly for our next ambitious project – assuming responsibility for collecting Victorian-wide cancer clinical trial data. This project will be delivered from 2023 onwards in partnership with the Victorian Cancer Agency within the Department of Health Victoria, and builds on the Cancer Council Victoria’s significant efforts in this space since 1988.
Cancer Trials Australia remains extremely well positioned to continue delivering unparalleled value to our expanding membership, helping to ensure Australian cancer patients can access novel, potentially life-saving therapies, as early as possible.
I thank all CTA staff, as well as our network Member personnel, for all the hard work they undertake that is essential to enable the CTA network to flourish.
Kurt Lackovic PhD MBA GAICD
Chief Executive Officer